Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Beats CAR-T Competitors To The Pricing Punch With Kymriah Approval

Executive Summary

Novartis got a leg up on its competition Aug. 30 with an earlier-than-expected approval for Kymriah in pediatric ALL, ending the CAR-T pricing mystery with its $475,000 price tag, which the company is positioning as a relative bargain.

You may also be interested in...



Payers Must Brace For Coming Wave Of Cell And Gene Therapies

One regenerative medicine for an ultra-rare disease may have a small impact, but payers will be flooded with dozens of new cell and gene therapies over the next few years. Enzyvant, Novartis and Spark share how they are positioning their complex products.

Novartis R&D Chief Tsai On 2019 Goals, Priorities, BD And Digital Advances

R&D head John Tsai spoke with Scrip about culture change at Novartis as it moves toward advanced therapy platforms and embraces digital technologies, and offered a peek into what’s in store for R&D in 2019 and beyond.

The Case For CAR-T Grows As Responses Hold Up Longer Term

Novartis and Gilead longer-term data show largely steady response and survival rates, shoring up the clinical and commercial case for their products and justifying continued investment in T-cell therapies. The CAR-T pioneers discuss their progress, including with allogeneic platforms, with Scrip at ASH.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1132679

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel